Experts Confront the Hidden Epidemic of Medication-Impaired Driving

ST. PETERSBURG, Fla. – April 15, 2026 – A silent but growing danger is unfolding on America's roads, not from alcohol or illicit substances, but from the contents of the household medicine cabinet. As the use of prescription and over-the-counter drugs skyrockets, a panel of national experts is set to address the complex challenge of medication-impaired driving at a major safety conference, highlighting a public health crisis that many drivers fail to recognize.

Dr. Gary Kay, a leading neuropsychologist and Chief Scientific Officer for Cognitive Research Corporation (CRC), will be a featured speaker at the 2026 Lifesavers Conference on Roadway Safety in Baltimore. From April 19-21, he will join federal regulators and top researchers to dissect the issue in a session titled, "Countermeasures, Regulations, & Research to Prevent Driving Under the Influence of Prescription & Over-the-Counter Medications." The discussion comes at a critical time, as statistics reveal a startling disconnect between medication use and public perception of risk.

A Public Health Crisis Hiding in Plain Sight

The scale of the issue is staggering. A 2021 survey revealed that nearly half of all U.S. drivers had used one or more potentially driver-impairing (PDI) medications within the past 30 days. More alarmingly, over 70% of those taking three or more such medications reported driving within two hours of a dose. These drugs, ranging from common allergy and sleep aids to prescription painkillers and antidepressants, can cause dizziness, slowed reaction time, blurred vision, and cognitive fog—all of which are antithetical to safe driving.

Despite these risks, a profound perception gap persists. While 66% of drivers view driving under the influence of alcohol as a very serious threat, only 28% feel the same about prescription drugs. This complacency has deadly consequences. Data shows that prescription drugs are the most common drug class found in fatally injured drivers, identified in 46.5% of such cases. This figure has risen steadily, paralleling a surge in prescriptions dispensed nationwide.

The trend of polypharmacy—the use of multiple drugs simultaneously—further complicates the matter, as interactions between medications, or with alcohol, can amplify impairing effects unpredictably.

Crafting a Regulatory and Scientific Response

Federal agencies are grappling with how to manage this multifaceted threat. The National Highway Traffic Safety Administration (NHTSA) has launched public awareness campaigns like "If You Feel Different, You Drive Different" to educate drivers. However, a significant hurdle remains: unlike alcohol's well-established link between blood concentration and impairment, the relationship is far less clear for most drugs. This ambiguity complicates both roadside enforcement and the establishment of legal limits.

In response, the U.S. Food and Drug Administration (FDA) is focusing on prevention at the source: drug development. In 2017, the agency finalized guidance for pharmaceutical companies, recommending a tiered approach to evaluating a new drug's potential impact on driving ability. This puts the onus on developers to conduct rigorous testing, often using sophisticated driving simulations, to understand how a product might affect a user's real-world functioning.

This is where the work of scientists like Dr. Kay and organizations like CRC becomes pivotal. With decades of experience consulting for both the FDA and NHTSA, Dr. Kay has been at the forefront of developing the scientific methodologies needed to meet these regulatory demands.

"Understanding how medications impact real-world functioning, including driving, requires both scientific rigor and practical application," Dr. Kay stated. "This conversation is critical as regulators, researchers, and developers work to ensure patient safety while maintaining the scientific standards required to support therapeutic development."

Pioneering Safety with Advanced Simulation

Cognitive Research Corporation, a neuroscience-focused contract research organization, has carved out a specialized niche in this field. The company conducts dedicated driving studies for pharmaceutical developers using its proprietary CRCDS MiniSim, an advanced driving simulator validated to detect impairment at levels equivalent to a 0.05% Blood Alcohol Content—the FDA's benchmark standard.

This technology allows researchers to safely and accurately measure a drug's effect on steering, lane position, reaction time, and vigilance in a controlled environment. CRC has conducted over 20 such studies, providing critical data that has directly influenced FDA-approved warning labels and usage guidelines for numerous medications. By simulating realistic driving scenarios, from monotonous highway vigilance tasks to complex urban navigation, these studies provide the actionable, regulator-ready results needed to bring safer drugs to market.

The upcoming panel at the Lifesavers Conference, one of the nation's largest gatherings of traffic safety professionals, will place this scientific work into a broader policy context. The discussion will explore how to translate complex research findings into clear guidance for doctors, pharmacists, and patients, and how to develop effective countermeasures to prevent tragedies.

The Next Frontier: Psychedelics and Evolving Therapies

The challenge is not static. The panel will also address the driving-related safety questions posed by emerging therapeutic classes, particularly psychedelics, which are gaining momentum in neuropsychiatric clinical development. As these powerful substances are explored for treating conditions like depression and PTSD, understanding their acute and residual effects on cognitive and psychomotor performance is a major public health priority.

CRC's experience in this vanguard area, including involvement in 10 psychedelic clinical trials, positions it to contribute essential data to this nascent field. The regulatory and scientific frameworks being built today will shape how these potentially life-changing therapies are integrated safely into society.

The conversation in Baltimore represents a crucial intersection of science, regulation, and public safety. By bringing together experts like Dr. Kay, the Lifesavers Conference aims to illuminate the hidden risks of medicated driving and forge a path toward solutions that protect both patients and the public on the nation's roadways.